SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue of $13.9 million, a 39.4% increase year over year, reflecting continued strong demand for its SSi Mantra surgical robotic system. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, signaling robust commercial traction and market acceptance.
The company's growth is driven primarily by system installations, which rose 30.4% to 30 systems during the quarter. The installed base now stands at 224 SSi Mantra systems across 12 countries, with a cumulative 12,272 surgeries performed. This expansion underscores the platform's global adoption and the company's ability to scale its operations in diverse healthcare markets.
Gross profit for the second quarter increased 20.0% to $7.1 million, although gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit increased 77.5% to $12.4 million, with an improved gross margin compared to the prior-year period. The margin dynamics reflect ongoing investments in scaling production and expanding the installed base.
Looking ahead, regulatory milestones in the U.S. and Europe could serve as significant catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. These approvals would open up two of the world's largest medical device markets, potentially accelerating adoption and revenue growth.
In addition to system sales, SS Innovations is extending the clinical profile of the SSi Mantra through telesurgery achievements. These advances demonstrate the platform's capabilities beyond traditional robotic surgery, potentially expanding its addressable market and reinforcing its competitive position.
The strong financial results and strategic milestones highlight the company's momentum in the surgical robotics sector. As the installed base grows and regulatory approvals approach, SS Innovations is well-positioned to capitalize on the increasing demand for minimally invasive surgical technologies. The company's focus on innovation and global expansion is expected to drive sustained growth in the coming quarters.
